MST1R
MOLECULAR TARGETmacrophage stimulating 1 receptor
MST1R (macrophage stimulating 1 receptor) is targeted by 32 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting MST1R
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | cabozantinib | 4.39 | 80 |
| 2 | foretinib | 4.34 | 76 |
| 3 | tozasertib | 4.33 | 75 |
| 4 | vandetanib | 4.30 | 73 |
| 5 | bosutinib | 4.08 | 58 |
| 6 | neratinib | 3.66 | 38 |
| 7 | tae 684 | 3.43 | 30 |
| 8 | gilteritinib | 3.40 | 29 |
| 9 | bms 777607 | 3.37 | 28 |
| 10 | linifanib | 3.33 | 27 |
| 11 | lestaurtinib | 3.04 | 20 |
| 12 | defosbarasertib | 2.89 | 17 |
| 13 | barasertib | 2.89 | 17 |
| 14 | r 406 | 2.83 | 16 |
| 15 | cediranib | 2.83 | 16 |
| 16 | milciclib | 2.77 | 15 |
| 17 | infigratinib | 2.77 | 15 |
| 18 | pha 665752 | 2.71 | 14 |
| 19 | kw 2449 | 2.64 | 13 |
| 20 | ast 487 | 2.56 | 12 |
| 21 | merestinib | 2.48 | 11 |
| 22 | bms 754807 | 2.30 | 9 |
| 23 | rebastinib | 2.20 | 8 |
| 24 | golvatinib | 2.20 | 8 |
| 25 | Crizotinib | 2.08 | 7 |
| 26 | cyc 116 | 2.08 | 7 |
| 27 | mk 2461 | 2.08 | 7 |
| 28 | fostamatinib | 2.08 | 7 |
| 29 | glesatinib | 2.08 | 7 |
| 30 | pf 03814735 | 1.79 | 5 |
| 31 | osi 632 | 1.79 | 5 |
| 32 | alsterpaullone | 0.69 | 1 |
About MST1R as a Drug Target
MST1R (macrophage stimulating 1 receptor) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 32 compounds with documented MST1R interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
MST1R inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.